Physician profile
Tyler Watson
NPI 1275190985
$4,615.24
in general payments reported to CMS, 2019-2025
23 companies · $2,819 in 2025
The $2,819 reported for 2025 was more than what 96% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $174 · 2024: $1,622 · 2025: $2,819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,615.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,601.19 | 2023-2025 | Rinvoq |
| Janssen Biotech, INC. | $1,332.08 | 2023-2025 | Tremfya, Simponi Aria |
| Amgen INC. | $387.56 | 2023-2025 | Krystexxa, Enbrel, Enbrel |
| Ucb, INC. | $226.55 | 2024-2025 | Bimzelx, Cimzia |
| Ani Pharmaceuticals, INC. | $194.99 | 2024-2025 | Purified Cortrophin Gel |
| Organon LLC | $114.65 | 2024-2025 | Hadlima, Renflexis |
| Fresenius Kabi USA, LLC | $96.25 | 2024-2025 | Idacio |
| Lilly USA, LLC | $70.86 | 2024-2025 | Taltz |
| Bioventus LLC | $69.93 | 2023-2025 | Durolane, Exogen Ultrasound Bone Healing System, Durolane |
| Novartis Pharmaceuticals Corporation | $66.27 | 2024 | |
| Sandoz INC. | $61.24 | 2024 | Hyrimoz |
| Sobi, INC | $59.80 | 2024-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $42.37 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $41.33 | 2025 | Saphnelo |
| Kyowa Kirin, INC. | $40.88 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electronic Waveform Lab, INC. | $40.14 | 2024-2025 | |
| Vertex Pharmaceuticals Incorporated | $31.79 | 2025 | |
| Spr Therapeutics, INC | $27.37 | 2025 | Sprint Pns System |
| Averitas Pharma INC. | $25.80 | 2024 | Qutenza |
| Trice Medical, INC. | $25.39 | 2024 | |
| Mallinckrodt Hospital Products INC. | $22.64 | 2025 | Acthar |
| Antares Pharma, INC. | $19.47 | 2024 | Xyosted |
| Ferring Pharmaceuticals INC. | $16.69 | 2025 | Euflexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.